Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press810.17650/2313-805X.2015.2.1.082-089RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИBiochemical criteria of toxicity of therapy with high doses of methotrexate in children with osteosarcomaБиохимические критерии токсичности терапии высокими дозами метотрексата у детей с остеосаркомойStrizhevskayaA. M.СтрижевскаяАлександра Михайловна
Russian Federation

Centralized Clinical and Laboratory Department, Research Institute of Clinical Oncology, 23 Kashirskoye Highway, Moscow, 115478, Russia

Централизованный клинико-лабораторный отдел, Россия, 115478, Москва, Каширское шоссе, 23

Strizhevsky@yandex.ruGolovnyaE. G.ГоловняЕ. Г.
Russian Federation

Centralized Clinical and Laboratory Department, Research Institute of Clinical Oncology, 23 Kashirskoye Highway, Moscow, 115478, Russia

Централизованный клинико-лабораторный отдел, Россия, 115478, Москва, Каширское шоссе, 23

DzampaevA. Z.ДзампаевА. З.
Russian Federation

Department of Musculoskeletal System, Research Institute of Children Hematology and Oncology, 23 Kashirskoye Highway, Moscow, 115478, Russia

отделение опорно-двигательного аппарата, Россия, 115478, Москва, Каширское шоссе, 23

BaykovaV. N.БайковаВ. Н.
Russian Federation

Centralized Clinical and Laboratory Department, Research Institute of Clinical Oncology, 23 Kashirskoye Highway, Moscow, 115478, Russia

Централизованный клинико-лабораторный отдел, Россия, 115478, Москва, Каширское шоссе, 23

N.N. Blokhin Russian Cancer Research CenterНИИ клинической онкологии ФГБНУ «РОНЦ им. Н.Н. Блохина»N.N. Blokhin Russian Cancer Research CenterНИИ детской онкологии и гематологии ФГБНУ «РОНЦ им. Н.Н. Блохина»15012015210820890206201502062015Copyright ©; 2015, Strizhevskaya A.M., Golovnya E.G., Dzampaev A.Z., Baykova V.N.Copyright ©; 2015, Стрижевская А.М., Головня Е.Г., Дзампаев А.З., Байкова В.Н.2015Strizhevskaya A.M., Golovnya E.G., Dzampaev A.Z., Baykova V.N.Стрижевская А.М., Головня Е.Г., Дзампаев А.З., Байкова В.Н.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/8

childrenhigh-dose methotrexatecancertherapeutic drug monitoringtoxicokineticstoxicityhomocysteineдетивысокие дозы метотрексатаостеосаркомытерапевтический лекарственный мониторингтоксикокинетикафармакокинетикагомоцистеин1. Соколов А.В. Терапевтический лекарственный мониторинг. Качественная клиническая практика 2002;(1):78–88. [Sokolov А.V. Therapeutic Drug Monitoring. Kachestvennaya klinicheskaya praktika = Good Clinical Practice 2002;(1):78–88. (In Russ.)].Соколов А.В. Терапевтический лекарственный мониторинг. Качественная клиническая практика 2002;(1):78–88. [Sokolov А.V. Therapeutic Drug Monitoring. Kachestvennaya klinicheskaya praktika = Good Clinical Practice 2002;(1):78–88. (In Russ.)].2. Ghculescu R.A. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr 2008;31:41–4.Ghculescu R.A. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr 2008;31:41–4.3. Lennard L. Therapeutic drug monitoring of antimetabolic cytotxic drugs. Br J Clin Pharmacol 1999;47(2):131–43.Lennard L. Therapeutic drug monitoring of antimetabolic cytotxic drugs. Br J Clin Pharmacol 1999;47(2):131–43.4. Мирошниченко И.И. Рациональное дозирование и мониторинг лекарственных средств: Практическое руководство. М.: Медицинское информационное агентство, 2011. 416 с. [Miroshnichenko I.I. Rational dosage and drug monitoring: Practical guide. Moscow: Meditsinskoe informatsionnoe agentstvo, 2011. 416 p. (In Russ.)].Мирошниченко И.И. Рациональное дозирование и мониторинг лекарственных средств: Практическое руководство. М.: Медицинское информационное агентство, 2011. 416 с. [Miroshnichenko I.I. Rational dosage and drug monitoring: Practical guide. Moscow: Meditsinskoe informatsionnoe agentstvo, 2011. 416 p. (In Russ.)].5. Bacci G., Briccoli A., Longhi A. et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005;44(7): 748–55.Bacci G., Briccoli A., Longhi A. et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005;44(7): 748–55.6. Копосов П.В., Ковалев В.И., Ковалев Д.В. Профилактика и лечение осложнений химиотерапии злокачественных опухолей у детей: современные подходы. Руководство для врачей. М.: Клевер Принт, 2002. С. 73–8. [Koposov P.V., Kovalev V.I., Kovalev D.V. Prevention and treatment of malignant tumours chemotherapy complications in children: modern approaches. Physician, s Guide. Moscow: Klever Print, 2002. Pp. 73–8. (In Russ.)].Копосов П.В., Ковалев В.И., Ковалев Д.В. Профилактика и лечение осложнений химиотерапии злокачественных опухолей у детей: современные подходы. Руководство для врачей. М.: Клевер Принт, 2002. С. 73–8. [Koposov P.V., Kovalev V.I., Kovalev D.V. Prevention and treatment of malignant tumours chemotherapy complications in children: modern approaches. Physician, s Guide. Moscow: Klever Print, 2002. Pp. 73–8. (In Russ.)].7. Crews K.R., Liu T., Rodriguez-Galindo C. et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004;100(8):1724–33.Crews K.R., Liu T., Rodriguez-Galindo C. et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004;100(8):1724–33.8. Bacci G., Ferrari S., Longhi A. et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 2003;10(4):851–7.Bacci G., Ferrari S., Longhi A. et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 2003;10(4):851–7.9. Hempel L., Misselwitz J., Fleck C. et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 2003;40(6):348–54.Hempel L., Misselwitz J., Fleck C. et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 2003;40(6):348–54.10. Broxson E., Stork L., Allen R. et al. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49(21):5879–83.Broxson E., Stork L., Allen R. et al. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49(21):5879–83.11. Rühs H., Becker A., Drescher A. et al. Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS One 2012;7(9):1–8.Rühs H., Becker A., Drescher A. et al. Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS One 2012;7(9):1–8.12. Sterba J., Dusek L., Demlova R., Valik D. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-hodgkin lymphoma: “folate overrescue” concept revisited. Clin Chem 2006;52(4):692–700.Sterba J., Dusek L., Demlova R., Valik D. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-hodgkin lymphoma: “folate overrescue” concept revisited. Clin Chem 2006;52(4):692–700.13. Refsum H., Wesenberg F., Ueland P.M. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51(3):828–35.Refsum H., Wesenberg F., Ueland P.M. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51(3):828–35.14. Refsum H., Ueland P., Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986;46(10):5385–91.Refsum H., Ueland P., Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986;46(10):5385–91.15. Refsum H., Smith A.D, Ueland P.M. et al. Homocysteine determinations: an expert opinion. Clin Chem 2004;50(1):3–32.Refsum H., Smith A.D, Ueland P.M. et al. Homocysteine determinations: an expert opinion. Clin Chem 2004;50(1):3–32.16. Valik D., Sterba J., Bajciova V., Demlova R. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005;69(3):269–72.Valik D., Sterba J., Bajciova V., Demlova R. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005;69(3):269–72.17. Holmboe L., Andersen A.M., Mørkrid L. et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 2011;73(1):106–14.Holmboe L., Andersen A.M., Mørkrid L. et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 2011;73(1):106–14.18. Watanabe K., Heike T., Kubota M. et al. Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity. Leuk Lymphoma 2013;3(1):1–5.Watanabe K., Heike T., Kubota M. et al. Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity. Leuk Lymphoma 2013;3(1):1–5.